Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost

JAMA. 2003 Jun 25;289(24):3229-30. doi: 10.1001/jama.289.24.3229.
No abstract available

Publication types

  • News

MeSH terms

  • Adjuvants, Immunologic / adverse effects
  • Adjuvants, Immunologic / economics
  • Adjuvants, Immunologic / therapeutic use*
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / economics
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / economics
  • Immunologic Factors / therapeutic use*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Adjuvants, Immunologic
  • Antirheumatic Agents
  • Immunologic Factors
  • Tumor Necrosis Factor-alpha